Last reviewed · How we verify
Ringer's Solution
Ringer's Solution is an intravenous electrolyte replacement fluid that restores fluid balance and electrolyte concentrations in the body.
Ringer's Solution is an intravenous electrolyte replacement fluid that restores fluid balance and electrolyte concentrations in the body. Used for Fluid resuscitation and volume replacement in hypovolemia, Maintenance of electrolyte balance in acute care and perioperative settings, Treatment of dehydration.
At a glance
| Generic name | Ringer's Solution |
|---|---|
| Also known as | Placebo, Ringer Acetate, Lactated Ringer's, Hartmann's Solution, RINGER LACTATE SOLUTION ALBERT DAVID |
| Sponsor | POLYSAN Scientific & Technological Pharmaceutical Company |
| Drug class | Crystalloid IV fluid / Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Fluid & Electrolyte Management |
| Phase | FDA-approved |
Mechanism of action
Ringer's Solution is a crystalloid IV fluid containing sodium, potassium, calcium, and chloride ions in concentrations approximating plasma. It is used to restore intravascular volume, maintain electrolyte homeostasis, and support tissue perfusion in dehydrated or hypovolemic patients. The balanced electrolyte composition makes it suitable for fluid resuscitation in trauma, surgery, and acute care settings.
Approved indications
- Fluid resuscitation and volume replacement in hypovolemia
- Maintenance of electrolyte balance in acute care and perioperative settings
- Treatment of dehydration
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hyperkalemia (if renal impairment present)
- Phlebitis at infusion site
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Effect of Liberal and Restrictive IV Fluids on Recovery After Gallbladder Surgery (PHASE1)
- Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy (PHASE2)
- Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement (PHASE2)
- Gelaspan vs Crystalloid Therapy in Sepsis (PHASE4)
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) (PHASE2)
- Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
- Volume Kinetics of Fluid Resuscitation in Early Sepsis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ringer's Solution CI brief — competitive landscape report
- Ringer's Solution updates RSS · CI watch RSS
- POLYSAN Scientific & Technological Pharmaceutical Company portfolio CI